<?xml version="1.0" encoding="UTF-8"?><html>
   <div tagx="ui">s13063-015-0568-6</div>
   <div tagx="ji">1745-6215</div>
   <head>
      <div tagx="dochead">Study protocol</div>
      <div tagx="bibl">
         <div tagx="title">
            <p>Population pharmacokinetic modeling of the Qishe pill in three major traditional Chinese
               medicine-defined constitutional types of healthy Chinese subjects: study protocol
               for a randomized controlled trial
            </p>
         </div>
         <ul tagx="aug">
            <li tagx="au">
               <span tagx="snm">Sun</span>
               <span tagx="fnm">Yue-li</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="edisonlike2008@gmail.com">edisonlike2008@gmail.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Hou</span>
               <span tagx="fnm">Ting</span>
               <span tagx="insr"></span>
               <a href="houting90@126.com">houting90@126.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Liu</span>
               <span tagx="fnm">Shu-fen</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="xiaoliufenfen@163.com">xiaoliufenfen@163.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Zhang</span>
               <span tagx="fnm">Zhong-liang</span>
               <span tagx="insr"></span>
               <a href="307779122@qq.com">307779122@qq.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Zhang</span>
               <span tagx="fnm">Ning</span>
               <span tagx="insr"></span>
               <a href="ningzh18@126.com">ningzh18@126.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Yao</span>
               <span tagx="fnm">Min</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="yaomin19871223@126.com">yaomin19871223@126.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Yang</span>
               <span tagx="fnm">Long</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="784472094@qq.com">784472094@qq.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Shi</span>
               <span tagx="fnm">Qi</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="jzyjs200032@126.com">jzyjs200032@126.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Cui</span>
               <span tagx="fnm">Xue-jun</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="13917715524@139.com">13917715524@139.com</a>
            </li>
            <li tagx="au">
               <span tagx="snm">Wang</span>
               <span tagx="fnm">Yong-jun</span>
               <span tagx="insr"></span>
               <span tagx="insr"></span>
               <a href="yjwang8888@126.com">yjwang8888@126.com</a>
            </li>
         </ul>
         <ul tagx="insg">
            <li tagx="ins">
               <p>Longhua Hospital, Shanghai University of Traditional Chinese Medicine, No. 725, South
                  Wanping Road, Shanghai 200032, P.R. China
               </p>
            </li>
            <li tagx="ins">
               <p>Spine Institute, Shanghai University of Traditional Chinese Medicine, No. 725, South
                  Wanping Road, Shanghai 200032, P.R. China
               </p>
            </li>
            <li tagx="ins">
               <p>College of Traditional Chinese Herbal Medicine, Shanghai University of Traditional
                  Chinese Medicine, No. 1200 Cailun Road, Shanghai 201203, P.R. China
               </p>
            </li>
            <li tagx="ins">
               <p>Zhe Jiang Biosia Pharmaceutical Co., Ltd, No.1938 Xinqun Road, Pinghu City, Zhejiang
                  Province, P.R. China
               </p>
            </li>
         </ul>
         <span tagx="source">Trials</span>
         <span tagx="issn">1745-6215</span>
         <span tagx="pubdate">2015</span>
         <span tagx="volume">16</span>
         <span tagx="issue">1</span>
         <span tagx="fpage">64</span>
         <a href="http://www.trialsjournal.com/content/16/1/64">http://www.trialsjournal.com/content/16/1/64</a>
         <div tagx="note">Yue-li Sun and Ting Hou contributed equally to this work.</div>
         <div tagx="xrefbib">
            <div tagx="pubidlist">
               <span tagx="pubid">10.1186/s13063-015-0568-6</span>
            </div>
         </div>
      </div>
      <div tagx="history">
         <span tagx="rec">
            <div tagx="date">
               <span tagx="day">6</span>
               <span tagx="month">11</span>
               <span tagx="year">2014</span>
            </div>
         </span>
         <span tagx="acc">
            <div tagx="date">
               <span tagx="day">16</span>
               <span tagx="month">1</span>
               <span tagx="year">2015</span>
            </div>
         </span>
         <span tagx="pub">
            <div tagx="date">
               <span tagx="day">26</span>
               <span tagx="month">2</span>
               <span tagx="year">2015</span>
            </div>
         </span>
      </div>
      <div tagx="cpyrt">
         <span tagx="year">2015</span>
         <div tagx="collab">Sun et al.; licensee BioMed Central.</div>
         <div tagx="note">This is an Open Access article distributed under the terms of the Creative Commons
            Attribution License (
            <a href="http://creativecommons.org/licenses/by/4.0">http://creativecommons.org/licenses/by/4.0</a>), which permits unrestricted use, distribution, and reproduction in any medium, provided
            the original work is properly credited. The Creative Commons Public Domain Dedication
            waiver (
            <a href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</a>) applies to the data made available in this article, unless otherwise stated.
         </div>
      </div>
      <ul tagx="kwdg">
         <li tagx="kwd">Personalized medicine</li>
         <li tagx="kwd">Individualized medicine</li>
         <li tagx="kwd">Traditional Chinese Medicine</li>
         <li tagx="kwd">Multiomics</li>
         <li tagx="kwd">Population pharmacokinetics</li>
      </ul>
      <div id="abstract" tag="abstract">
         <div id="">
            <div tagx="st">
               <h2>Abstract</h2>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Background</h3>
               </div>
               <p>High incidences of neck pain morbidity are challenging in various situations for populations
                  based on their demographic, physiological and pathological characteristics. Chinese
                  proprietary herbal medicines, as Complementary and Alternative Medicine (CAM) products,
                  are usually developed from well-established and long-standing recipes formulated as
                  tablets or capsules. However, good quantification and strict standardization are still
                  needed for implementation of individualized therapies. The Qishe pill was developed
                  and has been used clinically since 2009. The Qishe pill’s personalized medicine should
                  be documented and administered to various patients according to the ancient 
                  <i>TCM</i> system, a classification of personalized constitution types, established to determine
                  predisposition and prognosis to diseases as well as therapy and life-style administration.
                  Therefore, we describe the population pharmacokinetic profile of the Qishe pill and
                  compare its metabolic rate in the three major constitution types (
                  <i>Qi-</i>Deficiency, 
                  <i>Yin</i>-Deficiency and 
                  <i>Blood-</i>Stasis) to address major challenges to individualized standardized TCM.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Methods/Design</h3>
               </div>
               <p>Healthy subjects (N = 108) selected based on constitutional types will be assessed,
                  and standardized pharmacokinetic protocol will be used for assessing demographic,
                  physiological, and pathological data. Laboratory biomarkers will be evaluated and
                  blood samples collected for pharmacokinetics(PK) analysis and second-generation gene
                  sequencing. In single-dose administrations, subjects in each constitutional type cohort
                  (N = 36) will be randomly divided into three groups to receive different Qishe pill
                  doses (3.75, 7.5 and 15 grams).
               </p>
               <p>Multiomics, including next generation sequencing, metabolomics, and proteomics, will
                  complement the Qishe pill’s multilevel assessment, with cytochrome P450 genes as targets.
                  In a comparison with the general population, a systematic population pharmacokinetic
                  (PopPK) model for the Qishe pill will be established and verified.
               </p>
            </div>
            <div id="">
               <div tagx="st">
                  <h3>Trial registration</h3>
               </div>
               <p>This study is registered at ClinicalTrials.gov, 
                  <a href="NCT02294448">NCT02294448</a>.15 November 2014.
               </p>
            </div>
         </div>
      </div>
   </head>
   <div id="">
      <div tagx="st">
         <h2>Background</h2>
      </div>
      <p>Neck pain is one of the most common symptoms of cervical spine disease. Many treatments
         are available to patients and considered standard in clinical practice. They include
         common conservative strategies such as medication, physical methods, manual treatments,
         and education of patients. However, current evidence for the management of neck pain
         reveals that conservative interventions, especially Chinese herbal medicine, have
         not been studied in enough detail to assess their efficacy or effectiveness adequately
         
         <span tagx="abbrgrp">
            <span tagx="abbr">1</span>
         </span>. Possible reasons for the failure of current clinical practice to effectively manage
         neck pain lie in two main domains: first, the most difficult challenge faced is clinical
         heterogeneity, which appears at many levels, such as in the sample group, type of
         herbal medicine used and outcomes measured 
         <span tagx="abbrgrp">
            <span tagx="abbr">2</span>
         </span>; and second, although Chinese proprietary herbal medicines are usually based on well-established
         and long-standing recipes and formulated as tablets or capsules for commerce, convenience
         and/or palatability, good quantification and strict detailed standardization still
         need to be improved.
      </p>
      <p>As individualized diagnostic and therapeutic strategies have become a trend in modern
         medicine, they might help improve the efficacy and safety, predicting individual outcome
         and assessing risk, which make individualized prevention and early intervention strategies
         conceivable and practicable. According to the ancient 
         <i>TCM</i> system, a classification of individualized constitution types has been established
         to determine predisposition and prognosis to diseases as well as therapy and life-style
         administration 
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>. An official Classification and Determination of TCM Constitution 
         <span tagx="abbrgrp">
            <span tagx="abbr">4</span>
         </span> was released by the State Administration of TCM and the constitution branch of the
         Chinese Medical Association in April, 2009. Meanwhile, a standardized scale called
         Constitution in Chinese Medicine Questionnaire (CCMQ) 
         <span tagx="abbrgrp">
            <span tagx="abbr">5</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">7</span>
         </span> was designed based on the above classification. However, its reliability and validity
         has not been verified with comprehensive, large sample size trials. In the clinic,
         it takes a lot of practice for 
         <i>TCM</i> specialists to be really efficient at adopting the four 
         <i>TCM</i> examinations (observation, listening and smelling, inquiring, feeling the pulse and
         palpation) to totally assess the participants and determine their constitutional types
         based on physical, mental, physiological, and pathological attributes, which are called
         
         <i>Ti Zhi.</i> There are nine kinds of broad constitutional types with a varying degree of predisposition
         to different diseases (Table 
         <span tagx="tblr">1</span>). Among these, the three most contrasting constitutional types, 
         <i>Qi-</i>Deficiency, 
         <i>Yin</i>-Deficiency and 
         <i>Blood-</i>Stasis, are the most vulnerable to chronic musculoskeletal diseases 
         <span tagx="abbrgrp">
            <span tagx="abbr">3</span>
         </span>. In the realm of modern predictive medicine, efforts are being directed toward capturing
         disease phenotypes with greater precision for successful identification of markers
         for prospective disease conditions.
         
      </p>
      <table>
         <div tagx="title">
            <p>Table 1</p>
         </div>
         <caption>
            <p>
               <b>General characteristics of the nine traditional Chinese medicine</b>
               <i>(</i>
               <b>TCM) constitutional types</b>
               <span tagx="abbrgrp">
                  <span tagx="abbr">3</span>
               </span>,
               <span tagx="abbrgrp">
                  <span tagx="abbr">13</span>
               </span>,
               <span tagx="abbrgrp">
                  <span tagx="abbr">14</span>
               </span>
            </p>
         </caption>
         <tgroup>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <thead>
               <tr>
                  <td></td>
                  <td>
                     <p>
                        <b>General characteristics</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>Physical characteristics</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>Psychological characteristics</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>Sign of health</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>Sign of illness</b>
                     </p>
                  </td>
               </tr>
            </thead>
            <div tagx="tfoot">
               <p>*The three TCM constitutional types (Qi-deficiency, Yin-deficiency and Blood-stasis)
                  have been selected in this trial.
               </p>
            </div>
            <tbody>
               <tr>
                  <td>
                     <p>Gentleness</p>
                  </td>
                  <td>
                     <p>
                        <i>Yin-Yang</i> balanced
                     </p>
                  </td>
                  <td>
                     <p>Full of vitality and well-proportioned</p>
                  </td>
                  <td>
                     <p>Mild character</p>
                  </td>
                  <td>
                     <p>Good cold and hot tolerance, sleep well, good appetite and no fatigue</p>
                  </td>
                  <td>
                     <p>Less disease</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Type A</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <i>Qi-</i>deficiency
                        <sup>*</sup>
                     </p>
                  </td>
                  <td>
                     <p>Insufficiency of primordial 
                        <i>Qi</i>
                     </p>
                  </td>
                  <td>
                     <p>Weakened muscle
                        <sup>*</sup>
                     </p>
                  </td>
                  <td>
                     <p>No desire to speak</p>
                  </td>
                  <td>
                     <p>Short of breath, listless and low voice and easy to sweat and fatigue</p>
                  </td>
                  <td>
                     <p>Palpitations and influenza</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Type B</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <i>Yang</i>-deficiency
                     </p>
                  </td>
                  <td>
                     <p>More insufficiency of primordial 
                        <i>Qi</i>
                     </p>
                  </td>
                  <td>
                     <p>Slightly muscle atrophy</p>
                  </td>
                  <td>
                     <p>More quiet and introverted</p>
                  </td>
                  <td>
                     <p>Intolerance of cold, loose stool, clear abundant urine and easy to catch a cold</p>
                  </td>
                  <td>
                     <p>Diarrhea</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Type C</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <i>Yin</i>-deficiency
                        <sup>*</sup>
                     </p>
                  </td>
                  <td>
                     <p>
                        <i>Yin</i>-fluid deficiency
                     </p>
                  </td>
                  <td>
                     <p>Slim body</p>
                  </td>
                  <td>
                     <p>Quick-tempered</p>
                  </td>
                  <td>
                     <p>Feverish palms and soles, dry mouth and throat, dry eyes, flushing cheek, and dry
                        skin is usual
                     </p>
                  </td>
                  <td>
                     <p>Fatigue syndrome, muscle fatigue
                        <sup>*</sup> and insomnia
                     </p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Type D</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Phlegm-wetness</p>
                  </td>
                  <td>
                     <p>Body fluid stasis and phlegm-wetness aggregation</p>
                  </td>
                  <td>
                     <p>Obese body with accumulate fat around abdomen</p>
                  </td>
                  <td>
                     <p>Prudent</p>
                  </td>
                  <td>
                     <p>Feeling body heaviness, chest distress and excessive phlegm, sticky mouth, and sticky
                        sweating in usual
                     </p>
                  </td>
                  <td>
                     <p>Stroke and Diabetes</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Type E</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Wet-heat</p>
                  </td>
                  <td>
                     <p>Internal accumulation of damp-heat</p>
                  </td>
                  <td>
                     <p>Slim body</p>
                  </td>
                  <td>
                     <p>Tend to be irritable</p>
                  </td>
                  <td>
                     <p>likely to suffer from acne, thirsty, bad breath, bitter taste in the mouth in usual</p>
                  </td>
                  <td>
                     <p>Constipation, scabies and jaundice</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Type F</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Blood-stasis
                        <sup>*</sup>
                     </p>
                  </td>
                  <td>
                     <p>Poor blood circulation</p>
                  </td>
                  <td>
                     <p>All body types</p>
                  </td>
                  <td>
                     <p>Tend to be annoying and forgetful</p>
                  </td>
                  <td>
                     <p>Frequent pain
                        <sup>*</sup> and ecchymosis and gloomy complexion
                     </p>
                  </td>
                  <td>
                     <p>Chronic pain
                        <sup>*</sup>
                     </p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Type G</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <i>Qi-</i>depression
                     </p>
                  </td>
                  <td>
                     <p>Depression and stagnation of 
                        <i>Qi</i>
                     </p>
                  </td>
                  <td>
                     <p>Slim body</p>
                  </td>
                  <td>
                     <p>Depressive, sensitive and suspicious</p>
                  </td>
                  <td>
                     <p>Frequently sigh, distention and pain in chest</p>
                  </td>
                  <td>
                     <p>hypochondria</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Type H</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Special diathesis</p>
                  </td>
                  <td>
                     <p>Special diathesis</p>
                  </td>
                  <td>
                     <p>All body types</p>
                  </td>
                  <td>
                     <p>All types</p>
                  </td>
                  <td>
                     <p>Hypersensitiveness</p>
                  </td>
                  <td>
                     <p>Asthma and urticaria</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Type I</p>
                  </td>
               </tr>
            </tbody>
         </tgroup>
      </table>
      <p>In the early 1990s, the YQHYTL formula was proposed for neck pain and subsequently
         underwent further investigation to establish the medicine’s efficacy. Based on the
         YQHYTL formula, the Qishe pill (Shanghai Sundise Traditional Chinese Medicine Co.,
         Ltd, China), which is composed of processed 
         <i>Radix Astragali</i>, 
         <i>Muscone, Szechuan Lovage Rhizome</i>, 
         <i>Radix Stephaniae Tetrandrae</i>, 
         <i>Caulis Sinomenii</i>, and 
         <i>Calculus Bovis Artifactus</i> (Table 
         <span tagx="tblr">2</span>), was developed and has been widely used in clinical settings since 2009 
         <span tagx="abbrgrp">
            <span tagx="abbr">8</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">11</span>
         </span>. The Qishe pill is a thin 0.15 g film-coated pill with a slightly penetrating odor
         and a mildly bitter flavor. Production and processing of the Qishe pill are described
         as follows: (1) the volatile oil is extracted from 
         <i>Szechuan Lovage Rhizome</i> on standby; (2) the remaining drug decoction from 
         <i>Szechuan Lovage Rhizome</i> is mixed with 
         <i>Radix Astragali,</i> which has been soaked for 30 min, and simmered in 10 volumes of water, twice, for
         2 hours each time; (3) the decoction is then vacuum filtrated to a relative density
         of 1.24 to 1.26 (70°C), and ethanol is added to the concentrated decoction to bring
         to a 70% alcohol content; (4) after filtration and concentration (ethanol recovery),
         the remaining sample is vacuum dried and then crushed into a fine powder; (5) from
         this mixture, which contains 14 volumes of 70% ethanol, 
         <i>Radix Stephaniae Tetrandrae</i> and 
         <i>Caulis Sinomenii</i> are extracted with the circumfluent alcohol, three times for 2 hours, concentrated
         with recovery of ethanol, vacuum dried again, and crushed into a fine powder; (6)
         the volatile oil of 
         <i>Szechuan Lovage Rhizome</i> is then mixed with four parts β-cyclodextrin and dried under vacuum; and (7) the
         porphyrized powder of the 
         <i>Calculus Bovis Artifactus</i> and 
         <i>Muscone</i> are mixed with the β-cyclodextrin and the other two fine powders mentioned above,
         pelleted and coated, to obtain the pills called the Qishe pill (drug name).
         
      </p>
      <table>
         <div tagx="title">
            <p>Table 2</p>
         </div>
         <caption>
            <p>
               <b>Standard formula (capsule ingredients)*</b>
            </p>
         </caption>
         <tgroup>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <thead>
               <tr>
                  <td>
                     <p>
                        <b>Chinese Name</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>Pharmaceutical Name</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>Powered Herb, %</b>
                     </p>
                  </td>
               </tr>
            </thead>
            <div tagx="tfoot">
               <p>*Pharmaceutical terminology from Hsu 
                  <span tagx="abbrgrp">
                     <span tagx="abbr">12</span>
                  </span>.
               </p>
            </div>
            <tbody>
               <tr>
                  <td>
                     <p>Huang Qi</p>
                  </td>
                  <td>
                     <p>
                        <i>Radix Astragali</i>
                     </p>
                  </td>
                  <td>
                     <p>28% (13g)</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>She Xiang</p>
                  </td>
                  <td>
                     <p>
                        <i>Muscone</i>
                     </p>
                  </td>
                  <td>
                     <p>0. (0.03g)</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Chuan Xiong</p>
                  </td>
                  <td>
                     <p>
                        <i>Szechuan Lovage Rhizome</i>
                     </p>
                  </td>
                  <td>
                     <p>26% (12g)</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Fang Ji</p>
                  </td>
                  <td>
                     <p>
                        <i>Radix Stephaniae Tetrandrae</i>
                     </p>
                  </td>
                  <td>
                     <p>19% (9g)</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Qing Feng Teng</p>
                  </td>
                  <td>
                     <p>
                        <i>Caulis Sinomenii</i>
                     </p>
                  </td>
                  <td>
                     <p>26% (12g)</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>Niu Huang</p>
                  </td>
                  <td>
                     <p>
                        <i>Calculus Bovis Artifactus</i>
                     </p>
                  </td>
                  <td>
                     <p>0. (0.3g)</p>
                  </td>
               </tr>
            </tbody>
         </tgroup>
      </table>
      <p>With the high incidence of neck pain morbidity 
         <span tagx="abbrgrp">
            <span tagx="abbr">13</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">16</span>
         </span>, and the wide variety of population properties (age, gender, weight, constitutional
         type, history of disease and life style, etc.) involved, providing an individual patient
         with optimal treatment at a given time is challenging. Therefore, personalized administration
         of the Qishe pill should be documented and practiced with multiple patients. Thus,
         a comprehensive research concerning the population pharmacokinetics (PopPK) of the
         Qishe pill in Chinese subjects should be conducted. In this study, we describe the
         population pharmacokinetic profile of the Qishe pill and compare its extent of metabolism
         in the three major constitution types (
         <i>Qi-</i>Deficiency, 
         <i>Yin</i>-Deficiency and 
         <i>Blood</i>-Stasis) to address major challenges of individualized and standardized Traditional
         Chinese Medicine into clinical practice, as a pilot trial.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Methods/Design</h2>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study design</h3>
         </div>
         <p>This single-center, three cohort, open-label, double-Latin-sequence, crossover study
            will be conducted in 108 healthy adult subjects (36 subjects in each cohort) who meet
            the inclusion and exclusion criteria. The experiments will be conducted in accordance
            with good clinical practice procedures, all applicable regulatory requirements, and
            the guiding principles of the Declaration of Helsinki. This study was approved by
            the ethics committee of the institutional review board in Longhua Hospital, Shanghai
            University of TCM (2013-LCSY-064). After completing baseline description of the study
            to the enrolled subjects, written informed consent will be obtained from each of them.
         </p>
         <p>The sample size was established according to GCP guidelines of SFDA, which recommend
            8 to 12 subjects in a clinical pharmacokinetic trial. The study will take place at
            the phase I unit of Longhua Hospital, Shanghai University of TCM from Nov. 2014 to
            Dec 2016.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study population</h3>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Inclusion and exclusion criteria</h4>
            </div>
            <p>We will recruit three main cohorts with confirmed 
               <i>TCM</i> constitutional types: 
               <i>Qi-</i>Deficiency (n = 36), 
               <i>Yin</i>-Deficiency (n = 36) and 
               <i>Blood-</i>Stasis (n = 36). All subjects will be 20 to 35 years old and with normal weight (18.5
               kg/m
               <sup>2</sup> ≤BMI &lt;23.0 kg/m
               <sup>2</sup>). The detailed inclusion and exclusion criteria are presented in Table 
               <span tagx="tblr">3</span>.
               
            </p>
            <table>
               <div tagx="title">
                  <p>Table 3</p>
               </div>
               <caption>
                  <p>
                     <b>Inclusion and exclusion criteria</b>
                  </p>
               </caption>
               <tgroup>
                  <colspec></colspec>
                  <colspec></colspec>
                  <thead>
                     <tr>
                        <td></td>
                        <td>
                           <p>
                              <b>Criteria</b>
                           </p>
                        </td>
                     </tr>
                  </thead>
                  <tbody>
                     <tr>
                        <td>
                           <p>Inclusion</p>
                        </td>
                        <td>
                           <p>- Aged 20 to 35</p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- 18.5 kg/m
                              <sup>2</sup> ≤body mass index (BMI) &lt;23 kg/m
                              <sup>2</sup>
                           </p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- Traditional Chinese medicine (
                              <i>TCM)-</i>constitutionally typed as one  of the three major types
                           </p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>Exclusion</p>
                        </td>
                        <td>
                           <p>- History of impaired fasting glucose or diabetes mellitus (past history of diabetes
                              or fasting blood glucose at screening ≥100 mg/dl)
                           </p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- History of liver disease (hepatitis, hepatic cirrhosis) or hepatic dysfunction (AST
                              or ALT at screening ≥40 U/L)
                           </p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- History of renal dysfunction (creatinine at screening ≥1.2 mg/dl)</p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- History of heart disease (heart failure, angina pectoris, myocardial infarction,
                              arrhythmia)
                           </p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- History of malignant tumor</p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- Having digestive disorders that can interfere with normal absorption of standard
                              diet (gastritis, gastric ulcer, duodenitis, duodenal ulcer, etc.)
                           </p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- Smoking during the recent 3 months</p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- Alcohol consumption three or more times a week during the recent 3 months</p>
                        </td>
                     </tr>
                     <tr>
                        <td>
                           <p>- Women who were pregnant, intended to become pregnant, or breast- feeding</p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- Medicated during the recent month for therapeutic or prophylactic purposes</p>
                        </td>
                     </tr>
                     <tr>
                        <td></td>
                        <td>
                           <p>- Participating in another clinical trial</p>
                        </td>
                     </tr>
                  </tbody>
               </tgroup>
            </table>
            <p>All subjects will be surveyed beforehand for their demographic characteristics and
               lifestyle patterns. The screening will also include blood tests and the Constitution
               in Chinese Medicine Questionnaire (CCMQ). After exclusion of noneligible participants,
               the remaining subjects will be assigned identification codes.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Determination of TCM constitution</h3>
         </div>
         <p>According to Classification and Determination of TCM Constitution 
            <span tagx="abbrgrp">
               <span tagx="abbr">4</span>
            </span> released by the State Administration of TCM and the constitution branch of the Chinese
            Medical Association, two TCM specialists will adopt four 
            <i>TCM</i> examinations (observation, listening and smelling, inquiring, feeling the pulse and
            palpation) to totally assess the participants and determine their constitutional types
            based on physical, mental, physiological, and pathological attributes.
         </p>
         <p>The 
            <i>TCM</i> specialists involved are qualified traditional Chinese medical doctors licensed by
            the Chinese government, with 6 years of traditional Chinese medicine training, minimum
            3 years of training in 
            <i>TCM</i>, and 9 years of further clinical experience. The constitutional type will be confirmed
            only when both make concordant decisions. The Constitution in Chinese Medicine Questionnaire
            (CCMQ) 
            <span tagx="abbrgrp">
               <span tagx="abbr">5</span>
            </span>-
            <span tagx="abbrgrp">
               <span tagx="abbr">7</span>
            </span> will be used to improve objectiveness in decision-making.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Study procedures</h3>
         </div>
         <div id="">
            <div tagx="st">
               <h4>Laboratory measurements and clinical assessment</h4>
            </div>
            <p>A specific set of laboratory parameters will be measured for every subject on the
               day of recruitment. These parameters include blood count, electrolyte levels, renal
               and liver function parameters, blood lipid amounts. Furthermore, age, gender, history
               of smoking, blood pressure, weight (kg), and height (meters) will be obtained for
               all subjects. Standard operating procedures have been defined for each clinical examination,
               including the measurements of blood pressure, height and weight 
               <span tagx="abbrgrp">
                  <span tagx="abbr">17</span>
               </span>.
            </p>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Drug administration</h3>
         </div>
         <p>Thirty-six healthy adult subjects in each cohort will be randomly divided into three
            groups to receive three different doses (low, 3.75 g; middle, 7.5 g; or high, 15 g).
            Subjects will be randomly assigned following simple randomization procedures (computerized
            random numbers) to each subgroup. Each dose of the Qishe pill (Shanghai Sundise Traditional
            Chinese Medicine Co., Ltd, China) with the same lot number will be administered orally
            with water (240 ml) after at least 10-hour fast. The low dose (3.75 mg) was calculated
            according to the applicable regulatory guidance 
            <span tagx="abbrgrp">
               <span tagx="abbr">18</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">19</span>
            </span>, using the No Observable Adverse Effect Level (NOAEL) in the most sensitive species
            (500 mg/kg/day in Sprague–Dawley rats).
         </p>
         <p>Subjects will be admitted to the study unit the evening before drug administration.
            On the day of administration, single doses of the Qishe pill will be taken orally,
            1h after a standardized meal. Regular standardized meals will be provided 4 h after
            drug administration. Water is allowed as desired, except for 1 hour before and 2 hours
            after drug administration. The subjects will remain within a supervised investigational
            unit for the subsequent 3-d period for pharmacokinetic study and toxicity monitoring,
            providing 3-day blood and urine samples. Vital signs and clinical laboratory tests
            were done before and at 24 h after dosing. Furthermore, they will be requested to
            return to the study unit 4 d after drug administration for a follow-up visit.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Sample collection</h3>
         </div>
         <p>For the PK analysis and second-generation gene sequencing, 5 ml blood samples will
            be collected into tubes containing ammonium heparinate and centrifuged immediately
            at 4000 g for 10 min to obtain plasma samples. These samples will be then transferred
            into polypropylene vials and kept at −20°C until analysis. For the 7.5 and 15 g dose
            groups, samples will be collected at dosing (time 0), and 15, 30, 45, 60, 90, 120,
            150, 180, 240, 360, 480, 600, 720, 1440, 2160 and 2880 min.
         </p>
         <p>Furthermore, a comprehensive set of biomaterials including EDTA-plasma (6 ml), serum
            (5 ml) and urine (6 ml) will be collected and stored for future laboratory analyses.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Safety assessments</h3>
         </div>
         <p>Safety and tolerability will be assessed subjectively and objectively. Subjective
            tolerability will be assessed by questioning subjects about any adverse events (AE).
            Objective tolerability will be assessed at scheduled intervals by vital signs (body
            temperature, heart rate and blood pressure), electrocardiograms (ECGs), the examination
            of intravenous infusion sites, and identification of adverse events (AEs). AE information
            will be collected throughout the study, based on spontaneous volunteer reports, interviews,
            clinical examinations and laboratory tests (hematology, serum biochemistry, and urinalysis).
            The investigators will assess all clinical AEs according to the Medical Dictionary
            for Regular Activities criteria, in terms of intensity (mild, moderate, or severe),
            duration, outcome and relationship to the study drug. Those which are life threatening,
            or lead to death, hospitalization, disability, or medical intervention to prevent
            permanent impairment or damage, will be considered as serious adverse events (SAE).
            Each adverse event occurring to a subject has to be recorded in the case-report form.
         </p>
         <p>All study procedures are illustrated in Figure 
            <div tagx="figr">1</div>.
            
         </p>
         <div tagx="fig">
            <div tagx="title">
               <p>Figure 1</p>
            </div>
            <caption>
               <p>Patient flowchart detailing the process, including screening, allocation, and analysis.
                  
               </p>
            </caption>
            <div tagx="text">
               <p>
                  <b>Patient flowchart detailing the process, including screening, allocation, and analysis.</b>
               </p>
            </div>
            <div tagx="graphic"></div>
         </div>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Instrumentation and conditions</h3>
         </div>
         <p>The LC-MS/MS system consists of an ULTIMATE 3000 series UHPLC (Thermo Fisher Scientific,
            USA) coupled to a TSQ QUANTUM ACCESS MAX Mass Spectrometer (Thermo scientific, USA).
            Chromatographic separation will be performed on a Waters Acquity UPLC BEH C18 column
            [100 mm*2.1 mm (i.d.); 1.7μm] (Waters, USA). The standards and samples will be separated
            using a mobile phase consisting of 0.1% formic acid in water (solvent A) and methanol
            (solvent A). The gradient elution program will be: 0–1 min, 20% A; 1–8 min, 20-100%
            A; 8–12 min, 100% A; and then back to 20% A to recondition the column for 4 min. The
            flow rate of the mobile phase will be 0.3 ml/min, with the column temperature maintained
            at 40°C. ESI ionization performed in the positive ion mode with a spray voltage of
            3,000 V and negative mode with a spray voltage of 2500 V will be used. Sheath gas
            pressure and aux gas pressure will be set at 35 psi and 5 psi, respectively. A capillary
            temperature of 350°C will be used. Quantification will be performed in the multiple
            reaction monitoring (MRM) mode. The optimized parameters, such as collision energy
            (CE) and the tube lens for each compound, are summarized in Table 
            <span tagx="tblr">4</span>. Xcalibur (Ver. 2.1; Thermo scientific, USA) is used to control the UHPLC/TSQ Quantum
            system, and to acquire and process data.
            
         </p>
         <table>
            <div tagx="title">
               <p>Table 4</p>
            </div>
            <caption>
               <p>
                  <b>Multiple reaction monitoring (MRM) transitions for quantification of the nine target
                     compounds
                  </b>
               </p>
            </caption>
            <tgroup>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <colspec></colspec>
               <thead>
                  <tr>
                     <td>
                        <p>
                           <b>Compound abbreviations*</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Monitoring Mode</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Parent (m/z)</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Product (m/z)</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Tube lens (V)</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Collision energy (eV)</b>
                        </p>
                     </td>
                     <td>
                        <p>
                           <b>Retention times (min)</b>
                        </p>
                     </td>
                  </tr>
               </thead>
               <div tagx="tfoot">
                  <p>*The compound abbreviations and their associated terms:</p>
                  <p>AST-IV:  astragaloside IV; BER: berberine; CCS: calycosin; CCSG: calycosin-7-O-β-D-
                     glucoside; FAN: fangchinoline; FOR: formononetin; ONO: ononin; PAL: palmatine; 5-O-M:
                     5-O-methylvisammioside.
                  </p>
               </div>
               <tbody>
                  <tr>
                     <td>
                        <p>CCS</p>
                     </td>
                     <td>
                        <p>[M + H]+</p>
                     </td>
                     <td>
                        <p>285.16</p>
                     </td>
                     <td>
                        <p>270.30</p>
                     </td>
                     <td>
                        <p>99</p>
                     </td>
                     <td>
                        <p>23</p>
                     </td>
                     <td>
                        <p>6.43</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>CCSG</p>
                     </td>
                     <td>
                        <p>[M + H]+</p>
                     </td>
                     <td>
                        <p>447.24</p>
                     </td>
                     <td>
                        <p>285.30</p>
                     </td>
                     <td>
                        <p>98</p>
                     </td>
                     <td>
                        <p>20</p>
                     </td>
                     <td>
                        <p>4.89</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>FAN</p>
                     </td>
                     <td>
                        <p>[M + H]+</p>
                     </td>
                     <td>
                        <p>623.44</p>
                     </td>
                     <td>
                        <p>381.40</p>
                     </td>
                     <td>
                        <p>130</p>
                     </td>
                     <td>
                        <p>40</p>
                     </td>
                     <td>
                        <p>4.89</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>PAL</p>
                     </td>
                     <td>
                        <p>[M + H]+</p>
                     </td>
                     <td>
                        <p>352.23</p>
                     </td>
                     <td>
                        <p>336.30</p>
                     </td>
                     <td>
                        <p>89</p>
                     </td>
                     <td>
                        <p>29</p>
                     </td>
                     <td>
                        <p>5.44</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>5-O-M</p>
                     </td>
                     <td>
                        <p>[M + H]+</p>
                     </td>
                     <td>
                        <p>453.27</p>
                     </td>
                     <td>
                        <p>291.30</p>
                     </td>
                     <td>
                        <p>108</p>
                     </td>
                     <td>
                        <p>22</p>
                     </td>
                     <td>
                        <p>6.01</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>ONO</p>
                     </td>
                     <td>
                        <p>[M + H]+</p>
                     </td>
                     <td>
                        <p>431.25</p>
                     </td>
                     <td>
                        <p>269.30</p>
                     </td>
                     <td>
                        <p>97</p>
                     </td>
                     <td>
                        <p>17</p>
                     </td>
                     <td>
                        <p>6.00</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>FOR</p>
                     </td>
                     <td>
                        <p>[M + H]+</p>
                     </td>
                     <td>
                        <p>269.20</p>
                     </td>
                     <td>
                        <p>197.30</p>
                     </td>
                     <td>
                        <p>97</p>
                     </td>
                     <td>
                        <p>34</p>
                     </td>
                     <td>
                        <p>7.32</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>AST-IV</p>
                     </td>
                     <td>
                        <p>[M + Na]+</p>
                     </td>
                     <td>
                        <p>807.53</p>
                     </td>
                     <td>
                        <p>627.40</p>
                     </td>
                     <td>
                        <p>221</p>
                     </td>
                     <td>
                        <p>49</p>
                     </td>
                     <td>
                        <p>8.69</p>
                     </td>
                  </tr>
                  <tr>
                     <td>
                        <p>BER</p>
                     </td>
                     <td>
                        <p>[M + H]+</p>
                     </td>
                     <td>
                        <p>336.19</p>
                     </td>
                     <td>
                        <p>320.28</p>
                     </td>
                     <td>
                        <p>94</p>
                     </td>
                     <td>
                        <p>30</p>
                     </td>
                     <td>
                        <p>5.38</p>
                     </td>
                  </tr>
               </tbody>
            </tgroup>
         </table>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Analytical assays</h3>
         </div>
         <p>Plasma concentrations and urinary excretion rates of the Qishe pill will be determined
            for up to 48 h using high-performance liquid chromatography with fluorometric detection
            according to a method used previously 
            <span tagx="abbrgrp">
               <span tagx="abbr">20</span>
            </span>.
         </p>
         <p>For sample preparation, plasma samples (100 ml) will be mixed with 100 ml of internal
            standard (diphenhydramine, purchased from the National Institutes for Food and Drug
            Control, Beijing, China) working solution. The samples will be extracted with 11:1
            methanol–water (600 ml) by vortex-mixing for 1 min at high speed and centrifugation
            at 12,000xg for 10 min; 20 ml supernatant will be injected in the LC/MS/MS system
            for analysis.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Pharmacokinetic parameters</h3>
         </div>
         <p>The pharmacokinetic parameters of the Qishe pill will be estimated using noncompartmental
            methods. The actual blood sampling time will be used, and the maximum plasma concentration
            (
            <i>C</i>
            <sub>max</sub>) and time to maximum concentration (
            <i>T</i>
            <sub>max</sub>) will be recorded. The area under the plasma concentration-time curve (
            <i>AUC</i>) will be calculated using the linear trapezoidal rule. The elimination rate constant
            (
            <i>k</i>
            <sub>e</sub> ) will be estimated from the least-squares regression slope of the terminal plasma
            concentration. The 
            <i>AUC</i> from 0 to infinity (
            <i>AUC</i>
            <sub>0−∞</sub>) will be calculated by (
            <i>AUC</i>
            <sub>0→t</sub> + 
            <i>C</i>
            <sub>t</sub> /
            <i>k</i>
            <sub>e</sub> ) (
            <i>C</i>
            <sub>t</sub> is the last plasma concentration measured). The elimination half-life (t
            <sub>1/2</sub>) will be calculated as ln 2/
            <i>k</i>
            <sub>e</sub>. The distribution volume (DF) will be calculated by Dose/
            <i>AUC</i>/
            <i>k</i>
            <sub>e</sub>.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Deep phenotyping with genomics and functional genomics approaches</h3>
         </div>
         <p>Within pharmacokinetics of the Qishe pill, standardized workflows for the omics characterization
            of biosamples will be developed. Currently, genomic variants will be analyzed for
            144 subjects with the aid of the Human- CoreExome + v1.1-Psych Array. For a subset
            of 144 subjects, whole blood expression data will be generated using Illumina’s HT-12
            bead chips. The findings will be complemented with proteomic and metabolomic data
            using established workflows. Cytochrome P450 genes, such as CYP1A1, CYP1A2, CYP2D6,
            CYP2C9, CYP2C19, CYP2E1, CYP3A4 and CYP3A5, among other, will be the targets.
         </p>
         <p>Metabolomics provide comprehensive snapshots of the metabolome of body fluids such
            as plasma or urine. High-throughput metabolomic analyses mainly based on 1H nuclear
            magnetic resonance (NMR) spectroscopy, a nondestructive analysis with minimal preparation
            requirements, will be performed. NMR spectroscopy provides robust and reproducible
            measurements. Mass spectrometry (MS) with high analytical sensitivity will be used
            for additional detailed studies.
         </p>
         <p>Integrated analyses of these data for associations with clinical and subclinical phenotypes
            will be performed using the bioinformatics groups of the 
            <i>TCM</i> constitutional type classification.
         </p>
      </div>
      <div id="">
         <div tagx="st">
            <h3>Medical informatics and data management</h3>
         </div>
         <p>The PopPK analysis will be performed with NONMEM 
            <span tagx="abbrgrp">
               <span tagx="abbr">21</span>
            </span>-
            <span tagx="abbrgrp">
               <span tagx="abbr">23</span>
            </span>. The plasma concentration-time profiles for all constituents and derivatives of the
            Qishe pill will be described by a base structural model using the subroutine ADVAN5
            
            <span tagx="abbrgrp">
               <span tagx="abbr">24</span>
            </span>. The PK structural model will be parameterized in terms of apparent clearance and
            apparent distribution volume (CL/F and V/F), where F is the unknown oral bioavailability;
            the clearance and distribution volume are CL
            <sub>M</sub> and V
            <sub>M</sub>, respectively. A Bayesian approach conditioned on the population characteristics
            will be used to estimate specific individual parameters. First-order conditional estimation
            methods (FOCE) and first-order conditional estimation methods with interaction (FOCE-I)
            will be tested during model development. The unexplained random variability in individual
            values of the structural model parameters will be described in the interindividual
            variability (IIV) model.
         </p>
         <p>For the final model, a backward elimination process will be employed to identify significant
            covariates. The covariates in the full model will be excluded one by one. The objective
            function value (OFV) will be compared with that of the full model. A covariate will
            be retained in the model when its elimination results in an increase in the OFV of
            7.88 (chi-square, 
            <i>P</i> &lt;0.005, 
            <i>df</i> = 1). We will select the model according to the reduction in the OFV value, goodness-of-fit
            plots, reduction in the IIV of structure model parameters, residual error, robust
            model parameter estimation, and model stability. The architecture and basic elements
            of the PopPK research is illustrated in Figure 
            <div tagx="figr">2</div>.
            
         </p>
         <div tagx="fig">
            <div tagx="title">
               <p>Figure 2</p>
            </div>
            <caption>
               <p>Architecture and basic elements of the population pharmacokinetic (PopPK) research
                  based on medical informatics and data management. 
               </p>
            </caption>
            <div tagx="text">
               <p>
                  <b>Architecture and basic elements of the population pharmacokinetic (PopPK) research
                     based on medical informatics and data management.
                  </b>
               </p>
            </div>
            <div tagx="graphic"></div>
         </div>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Discussion</h2>
      </div>
      <p>Cervical radiculopathy is a significant public health problem worldwide, accounting
         for 60 to 70% of all cervical spondylopathy cases; it is generally believed that most
         symptoms can be cured or relieved by nonsurgical treatments 
         <span tagx="abbrgrp">
            <span tagx="abbr">25</span>
         </span>.
      </p>
      <p>Previous evidence-based trials have reported that analgesics and nerve-nutrition medicines
         have considerable effects on neck pain. Even though analgesics, such as aspirin, seem
         to be relatively safe, gastrointestinal reactions are often reported after their use
         
         <span tagx="abbrgrp">
            <span tagx="abbr">26</span>
         </span>. Mecobalamin, a neuropathy drug, which relieves neck pain by stimulating the inhibition
         of nerve degeneration and improving the excitability of nerve fibers 
         <span tagx="abbrgrp">
            <span tagx="abbr">27</span>
         </span>, seems to be ineffective when degeneration occurs.
      </p>
      <p>The Qishe pill provides specific benefits for “Qi and Blood”, terms in 
         <i>TCM</i>, meaning that it can profit and activate blood circulation. We have previously shown
         that the Qishe pill reversibly inhibits the NF-κB pathway, which might be an underlying
         mechanism behind its anti-inflammatory potential in disc degeneration 
         <i>in vivo</i>
         <span tagx="abbrgrp">
            <span tagx="abbr">28</span>
         </span>. Extensive investigations have confirmed that the Qishe pill has several therapeutic
         features, inhibiting platelet surface activity and platelet aggregation 
         <span tagx="abbrgrp">
            <span tagx="abbr">29</span>
         </span>, reducing the synthesis and release of local PGE 
         <span tagx="abbrgrp">
            <span tagx="abbr">30</span>
         </span>, decreasing malondialdehyde content in inflammatory exudates 
         <span tagx="abbrgrp">
            <span tagx="abbr">31</span>
         </span>, and inhibiting the IL-1beta-induced phosphorylation of extracellular signal-regulated
         kinases 1/2 and c-Jun N-terminal kinase 
         <span tagx="abbrgrp">
            <span tagx="abbr">32</span>
         </span>
         <sub>.</sub> These effects include predictable pharmacokinetics (PK) and pharmacodynamics (PD)
         behaviors; in addition, the Qishe pill suppresses acute inflammatory reactions and
         pain events with fewer gastrointestinal discomfort and rash. A simple and sensitive
         method using ultra-high-performance liquid chromatography–tandem mass spectrometry
         (UHPLC–MS/MS) on a reverse-phase C18 column was developed for the simultaneous determination
         of the 19 major components of the Qishe pill 
         <span tagx="abbrgrp">
            <span tagx="abbr">20</span>
         </span>. This method was successfully validated for the quantification of the 19 components
         in the Qishe pill products, and constitutes a new standard in quality assessment of
         TCM prescriptions containing multiple bioactive components (see Additional file 
         <div tagx="supplr">1</div>). Over the last few years, several interactions between the Qishe pill ingredients
         and the pharmacokinetics of flavonoids (calycosin and calycosin-7-o--d-glycoside),
         alkaloids (tetrandrine, fangchinoline, magnoflorine and berberine hydrochloride),
         ferulic acid and glycosides (astragaloside IV, astragalussaponin I and III) have been
         reported 
         <span tagx="abbrgrp">
            <span tagx="abbr">20</span>
         </span>,
         <span tagx="abbrgrp">
            <span tagx="abbr">33</span>
         </span>-
         <span tagx="abbrgrp">
            <span tagx="abbr">37</span>
         </span>. Furthermore, HPLC-TQ/MS was employed to detect the component contents in the Qishe
         pill, whose partial pharmacokinetic parameters are shown in Table 
         <span tagx="tblr">5</span>.
         
      </p>
      <table>
         <div tagx="title">
            <p>Table 5</p>
         </div>
         <caption>
            <p>
               <b>Pharmacokinetic parameter after oral administration of Qishe pill at a dose of 6.33
                  g•kg-1 to SD rats (mean ± SD, n = 6)
               </b>
            </p>
         </caption>
         <tgroup>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <colspec></colspec>
            <thead>
               <tr>
                  <td>
                     <p>
                        <b>Parameters</b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>
                           <i>SEA</i>
                        </b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>
                           <i>SEI</i>
                        </b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>
                           <i>FOR</i>
                        </b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>
                           <i>ONO</i>
                        </b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>
                           <i>5-O-M</i>
                        </b>
                     </p>
                  </td>
                  <td>
                     <p>
                        <b>
                           <i>AST-IV</i>
                        </b>
                     </p>
                  </td>
               </tr>
            </thead>
            <tbody>
               <tr>
                  <td>
                     <p>
                        <b>
                           <i>t</i>
                        </b>
                        <sub>1/2</sub>
                        <b>(h)</b>
                     </p>
                  </td>
                  <td>
                     <p>22.72 ± 11.49</p>
                  </td>
                  <td>
                     <p>12.35 ± 10.3</p>
                  </td>
                  <td>
                     <p>51.24 ± 44.19</p>
                  </td>
                  <td>
                     <p>7.04 ± 3.7</p>
                  </td>
                  <td>
                     <p>42.79 ± 16.29</p>
                  </td>
                  <td>
                     <p>11.41 ± 12.51</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <b>
                           <i>C</i>
                        </b>
                        <sub>max</sub>
                        <b>(ng/ml)</b>
                     </p>
                  </td>
                  <td>
                     <p>53.71 ± 16.14</p>
                  </td>
                  <td>
                     <p>136.51 ± 45.24</p>
                  </td>
                  <td>
                     <p>9.39 ± 4.32</p>
                  </td>
                  <td>
                     <p>2.45 ± 1.51</p>
                  </td>
                  <td>
                     <p>0.14 ± 0.07</p>
                  </td>
                  <td>
                     <p>13.3 ± 5.42</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <b>
                           <i>T</i>
                        </b>
                        <sub>max</sub>
                        <b>(h)</b>
                     </p>
                  </td>
                  <td>
                     <p>0.22 ± 0.07</p>
                  </td>
                  <td>
                     <p>0.31 ± 0.16</p>
                  </td>
                  <td>
                     <p>0.22 ± 0.07</p>
                  </td>
                  <td>
                     <p>0.25 ± 0.00</p>
                  </td>
                  <td>
                     <p>0.25 ± 0.00</p>
                  </td>
                  <td>
                     <p>2.00 ± 2.25</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <b>
                           <i>AUC</i>
                        </b>
                        <sub>last</sub>(h*ng/ml)
                     </p>
                  </td>
                  <td>
                     <p>606.87 ± 161.89</p>
                  </td>
                  <td>
                     <p>851.3 ± 251.31</p>
                  </td>
                  <td>
                     <p>38.1 ± 8.04</p>
                  </td>
                  <td>
                     <p>4.17 ± 1.53</p>
                  </td>
                  <td>
                     <p>1.13 ± 0.10</p>
                  </td>
                  <td>
                     <p>107.74 ± 65.65</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <b>
                           <i>AUC</i>
                        </b>
                        <sub>tot</sub>(h*ng/ml)
                     </p>
                  </td>
                  <td>
                     <p>826.3 ± 229.51</p>
                  </td>
                  <td>
                     <p>900.76 ± 236.67</p>
                  </td>
                  <td>
                     <p>71.57 ± 26.49</p>
                  </td>
                  <td>
                     <p>4.89 ± 1.65</p>
                  </td>
                  <td>
                     <p>2.31 ± 0.41</p>
                  </td>
                  <td>
                     <p>129.75 ± 61.01</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <b>
                           <i>MRT</i>
                        </b>
                        <b>(h)</b>
                     </p>
                  </td>
                  <td>
                     <p>36.54 ± 15.27</p>
                  </td>
                  <td>
                     <p>16.58 ± 6.89</p>
                  </td>
                  <td>
                     <p>70.4 ± 60.63</p>
                  </td>
                  <td>
                     <p>9.55 ± 4.04</p>
                  </td>
                  <td>
                     <p>65.96 ± 20.60</p>
                  </td>
                  <td>
                     <p>17.9 ± 17.38</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <b>
                           <i>CL</i>
                        </b>
                        <b>(L/h/kg)</b>
                     </p>
                  </td>
                  <td>
                     <p>0.05 ± 0.01</p>
                  </td>
                  <td>
                     <p>0.02 ± 0.01</p>
                  </td>
                  <td>
                     <p>0.02 ± 0.00</p>
                  </td>
                  <td>
                     <p>0.12 ± 0.05</p>
                  </td>
                  <td>
                     <p>0.16 ± 0.03</p>
                  </td>
                  <td>
                     <p>0.06 ± 0.07</p>
                  </td>
               </tr>
               <tr>
                  <td>
                     <p>
                        <b>
                           <i>V</i>
                        </b>
                        <b>z (L/kg)</b>
                     </p>
                  </td>
                  <td>
                     <p>1.41 ± 0.67</p>
                  </td>
                  <td>
                     <p>0.41 ± 0.33</p>
                  </td>
                  <td>
                     <p>0.98 ± 0.43</p>
                  </td>
                  <td>
                     <p>1.12 ± 0.83</p>
                  </td>
                  <td>
                     <p>9.38 ± 2.09</p>
                  </td>
                  <td>
                     <p>0.83 ± 0.94</p>
                  </td>
               </tr>
            </tbody>
         </tgroup>
      </table>
      <p>In the pre-trial of limited size (n = 6), accordingly, a UPLC-TQ/MS method for simultaneous
         determination of plasma concentrations of 15 bio-active Qishe pill constituents was
         developed and validated. The results showed that the method was selective, sensitive,
         precise, accurate, and reliable for comparative quantification of ferulic acid, calycosin,
         calycosin glycosides,calycosin-7-O-β-glucoside, ononin, formononetin, astragaloside,
         tetrandrine, fangchinoline base, berberine, tetrahydroberberine, tetrahydropalmatine,
         sinomenine and magnolia base, in human plasma samples. The mean plasma concentration–time
         profiles of the major bio-active components determined after oral administration of
         Qishe pills are illustrated in Figure 
         <div tagx="figr">3</div>.
         
      </p>
      <div tagx="fig">
         <div tagx="title">
            <p>Figure 3</p>
         </div>
         <caption>
            <p>Mean plasma concentration-time curves of seven components after oral administration
               of the Qishe pill at medium and high dosages (n = 4). 
            </p>
         </caption>
         <div tagx="text">
            <p>
               <b>Mean plasma concentration-time curves of seven components after oral administration
                  of the Qishe pill at medium and high dosages (n = 4).
               </b>
            </p>
         </div>
         <div tagx="graphic"></div>
      </div>
      <p>According to the results of the pilot trial, further research should be conducted
         with modified protocol in dosage setting, requirements of sample collection (diet
         specifications, blood-collection time window) and sample processing.
      </p>
      <div id="">
         <div tagx="st">
            <h3>Highlights</h3>
         </div>
         <p>Diagnosis and treatment based on an overall analysis of the illness and patient’s
            condition is the essence of the 
            <i>TCM</i> theory. Rational medication is dependent upon a basic understanding of the way patients
            handle drugs (pharmacokinetics) and their response to specific drug effects (pharmacodynamics).
            Moreover, 
            <i>TCM</i> constitutional types in traditional Chinese recipes could significantly influence
            the plasma concentration-time and their pharmacokinetic parameters after oral administration
            
            <span tagx="abbrgrp">
               <span tagx="abbr">38</span>
            </span>,
            <span tagx="abbrgrp">
               <span tagx="abbr">39</span>
            </span>. As data collection and OMICS analyses in PopPK of the Qishe pill will be processed
            simultaneously, research is focusing on the analyses of PK, OMICS and laboratory data
            to generate new hypotheses for translational research such as individualized dose,
            individualized scope of 
            <i>TCM</i> and trial simulation.
         </p>
         <p>The present study will establish three cohorts to detect potential differences in
            pharmacokinetic characteristics of the Qishe pill constituents in the three different
            
            <i>TCM</i> constitutional types, to assess whether the rate and extent of drug metabolism will
            be altered in 
            <i>Qi-</i>deficiency or 
            <i>Blood</i>-stasis constitutional types. If the differences in the Qishe Pill pharmacokinetics
            among the three major constitutional groups were known, personalized medication strategies
            for people with the three major constitutional types could be provided for the application
            of TCM.
         </p>
      </div>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Trial status</h2>
      </div>
      <p>Participant recruitment and prescreening began in December 2014. Blank control serum
         samples have been collected for standardization of the general methodology and normal
         conditions.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Abbreviations</h2>
      </div>
      <p>AST-III: Astragaloside III</p>
      <p>AST-IV: Astragaloside IV</p>
      <p>
         <i>AUC</i> : area under the plasma concentration–time curve
      </p>
      <p>BER: Berberine</p>
      <p>CA: Cholic acid</p>
      <p>CCS: Calycosin</p>
      <p>CCSG: Calycosin-7-O-β-D- glucoside</p>
      <p>CE: Collision energy</p>
      <p>
         <i>C</i>
         <sub>max</sub>: Maximum plasma concentration
      </p>
      <p>DF: Distribution volume</p>
      <p>CL/F: Apparent clearance</p>
      <p>CL
         <sub>M</sub>: Clearance
      </p>
      <p>DAI: Daidzein</p>
      <p>FAN: Fangchinoline</p>
      <p>FOCE: First-order conditional estimation methods</p>
      <p>FOCE-I: First-order conditional estimation methods with interaction</p>
      <p>FOR: Formononetin</p>
      <p>GA: Gallic acid</p>
      <p>
         <i>k</i>
         <sub>e</sub>: Elimination rate constant
      </p>
      <p>MS: Mass spectrometry</p>
      <p>MRM: Multiple reaction monitoring</p>
      <p>NMR: Nuclear magnetic resonance</p>
      <p>OFV: Objective function value</p>
      <p>ONO: Ononin</p>
      <p>PAL: Palmatine</p>
      <p>PD: Pharmacodynamics</p>
      <p>PK: Pharmacokinetics</p>
      <p>PopPK: Population pharmacokinetic</p>
      <p>SEA: Senkyunolide A</p>
      <p>SEI: Senkyunolide I</p>
      <p>SIN: Sinomenine</p>
      <p>TCM: Traditional Chinese Medicine</p>
      <p>
         <i>T</i>
         <sub>max</sub>: Time to maximum concentration
      </p>
      <p>UHPLC–MS/MS: Ultra-high-performance liquid chromatography–tandem mass spectrometry</p>
      <p>V/F: Apparent distribution volume</p>
      <p>V
         <sub>M</sub>: Distribution volume
      </p>
      <p>5-O-M: 5-O-methylvisammioside</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Competing interests</h2>
      </div>
      <p>The authors declare that they have no competing interests.</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ contributions</h2>
      </div>
      <p>YLS participated in the study design, drafted the manuscript, and conducted the clinical
         procedure and sample collection. TH participated in the study design, revised the
         manuscript, and conducted the PK analysis and statistical modeling. SFL and ZLZ participated
         in statistical design and conducted the preliminary animal PK/PD analysis. MY and
         LY conducted the clinical procedure and sample collection. QS formulated the Qishe
         pill and provided academic advice in the Qishe pill administration. YJW, NZ and XJC
         gave administrative support for the study. YJW is the general supervisor for this
         research and participated in both the study design and critical revision of the manuscript.
         All authors read and approved the final manuscript.
      </p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Authors’ information</h2>
      </div>
      <p>Yue-li Sun and Ting Hou are co-first authors.</p>
   </div>
   <div id="">
      <div tagx="st">
         <h2>Additional file</h2>
      </div>
      <div tagx="suppl">
         <div tagx="title">
            <p>Additional file 1:</p>
         </div>
         <div tagx="text">
            <p>
               <b>Typical chromatograms of ultrahigh-performance LC and tandem mass spectrometry (UHPLC-MS/MS)
                  for (a) the mixed standard substance and (b) a sample [
               </b>
               <span tagx="abbrgrp">
                  <span tagx="abbr">32</span>
               </span>
               <b>].</b>
            </p>
         </div>
         <div tagx="file">
            <p>Click here for file</p>
         </div>
      </div>
   </div>
   <div tagx="bm">
      <div tagx="ack">
         <div id="">
            <div tagx="st">
               <h2>Acknowledgements</h2>
            </div>
            <p>The National TCM clinical research base was supported by State Administration of Traditional
               Chinese Medicine; Clinical Research Project of Traditional Chinese Medicine was supported
               by the State Administration of Traditional Chinese Medicine (201107004), “Three-year”
               project for promoting development of TCM in Shanghai (2014-2016) supported by Shanghai
               Municipal Commission of Health and Family Planning(ZY3-CCCX-3-2005); Selection and
               training project for excellent technician of Shanghai University of Traditional Chinese
               Medicine; “Shu Guang” project supported by Shanghai Municipal Education Commission;
               Shanghai Education Development Foundation(10GG20); Longhua Medical Team Project (LYTD-13);
               “Project Grant” supported by National Science Fund of China (81373666); “Innovation
               Team” development projects supported by Ministry of Education (IRT1270); “TCM Key
               projects” were supported by dept. of Science and Technology in Shanghai (14401970401).
            </p>
         </div>
      </div>
      <div tagx="refgrp">
         <div tagx="bibl">
            <div tagx="title">
               <p>Conservative management of mechanical neck pain: systematic overview and meta-analysis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Aker</span>
                  <span tagx="fnm">PD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gross</span>
                  <span tagx="fnm">AR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Goldsmith</span>
                  <span tagx="fnm">CH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Peloso</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">BMJ</span>
            <span tagx="pubdate">1996</span>
            <span tagx="volume">313</span>
            <span tagx="issue">7068</span>
            <span tagx="fpage">1291</span>
            <span tagx="lpage">6</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1136/bmj.313.7068.1291</span>
                  <span tagx="pubid">8942688</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Cui X, Trinh K, Wang YJ. Chinese herbal medicine for chronic neck pain due to cervical
               degenerative disc disease. Cochrane Database Syst Rev. 2010; (1), CD006556
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Wang Q. Classification of the nine basic 
               <i>TCM</i> constitutional type and based expression and diagnosis. J Beijing University Tradit
               Chin Med. 2005(04); 1-8.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Epidemiological investigation of constitutional types of Chinese medicine in general
                  population: Base on 21,948 epidemiological investigation data of nine provinces in
                  China
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhu</span>
                  <span tagx="fnm">YB</span>
               </li>
            </ul>
            <span tagx="source">ZhongHuaZhong Yi Yao ZaZhi</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">24</span>
            <span tagx="fpage">7</span>
            <span tagx="lpage">12</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Primary compiling of constitution in Chinese Medicine questionnaire</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhu</span>
                  <span tagx="fnm">YB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Xue</span>
                  <span tagx="fnm">HS</span>
               </li>
            </ul>
            <span tagx="source">ZhongGuo Lin Chuang Kang Fu</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">10</span>
            <span tagx="fpage">12</span>
            <span tagx="lpage">4</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Preliminary assessment on performance of constitution in Chinese medicine questionnaire</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Zhu</span>
                  <span tagx="fnm">YB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Xue</span>
                  <span tagx="fnm">HS</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Origasa</span>
                  <span tagx="fnm">H</span>
               </li>
            </ul>
            <span tagx="source">ZhongGuo Lin Chuang Kang Fu</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">10</span>
            <span tagx="fpage">15</span>
            <span tagx="lpage">7</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Evaluation on reliability and validity of the constitution in Chinese medicine questionnaire
                  (CCMQ)
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Zhu</span>
                  <span tagx="fnm">YB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Origasa</span>
                  <span tagx="fnm">H</span>
               </li>
            </ul>
            <span tagx="source">ZhongGuo Xing Wei Yi XueKeXue</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">16</span>
            <span tagx="fpage">651</span>
            <span tagx="lpage">4</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Purification process research of major compound in Qishe Pill as Astragalus</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Mei</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">YJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shi</span>
                  <span tagx="fnm">Q</span>
               </li>
            </ul>
            <span tagx="source">Acta Chin Med Pharmacol</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">34</span>
            <span tagx="fpage">14</span>
            <span tagx="lpage">6</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Quality standard research of Qishe Pill</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">YQ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Liu</span>
                  <span tagx="fnm">XH</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Liu</span>
                  <span tagx="fnm">M</span>
               </li>
            </ul>
            <span tagx="source">Lishizhen Med Mater Med Res</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">19</span>
            <span tagx="fpage">977</span>
            <span tagx="lpage">9</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Technology research of Qishe Pill, a new medicine for cervical spondylosis</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Liu</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">N</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">YJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">YQ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhou</span>
                  <span tagx="fnm">CJ</span>
               </li>
            </ul>
            <span tagx="source">Lishizhen Med Mater Med Res</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">21</span>
            <span tagx="fpage">176</span>
            <span tagx="lpage">9</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effects of Qishe Pill, a compound traditional Chinese herbal medicine, on cervical
                  radiculopathy: a randomized controlled trial for Phase III
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Ge</span>
                  <span tagx="fnm">JR</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">HM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Meng</span>
                  <span tagx="fnm">CX</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tong</span>
                  <span tagx="fnm">PJ</span>
               </li>
            </ul>
            <span tagx="source">Chin J New Drugs Clin</span>
            <span tagx="pubdate">2014</span>
            <span tagx="volume">7</span>
            <span tagx="fpage">56</span>
            <span tagx="lpage">8</span>
         </div>
         <div tagx="bibl">
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Hsu</span>
                  <span tagx="fnm">H-Y</span>
               </li>
            </ul>
            <span tagx="source">1986 Oriental MateriaMedica</span>
            <div tagx="publisher">Oriental Healing Arts Institute, Long Beach, CA</div>
            <span tagx="pubdate">1986</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>U.S. Department of Health, Education, and Welfare. Basic data on arthritis knee, hip
                  and sacroiliac joints in adults ages 25–74 years: United States, 1971–1975
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Maurer</span>
                  <span tagx="fnm">K</span>
               </li>
            </ul>
            <span tagx="source">Health Stat</span>
            <span tagx="pubdate">1979</span>
            <span tagx="volume">11</span>
            <span tagx="fpage">1</span>
            <span tagx="lpage">31</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Prevalence, determinants, and consequences of chronic neck pain in Finland</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Mäkelä</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Heliövaara</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sievers</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Impivaara</span>
                  <span tagx="fnm">O</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Knekt</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Aromaa</span>
                  <span tagx="fnm">A</span>
               </li>
            </ul>
            <span tagx="source">Am J Epidemiol</span>
            <span tagx="pubdate">1991</span>
            <span tagx="volume">134</span>
            <span tagx="fpage">1356</span>
            <span tagx="lpage">67</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">1755449</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Neck pain in the general population</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bovim</span>
                  <span tagx="fnm">G</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schrader</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Sand</span>
                  <span tagx="fnm">T</span>
               </li>
            </ul>
            <span tagx="source">Spine (Phila Pa 1976)</span>
            <span tagx="pubdate">1994</span>
            <span tagx="volume">19</span>
            <span tagx="fpage">1307</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1097/00007632-199406000-00001</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>The associations of neck pain with radiological abnormalities of the cervical spine
                  and personality traits in a general population
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Van der Donk</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Schouten</span>
                  <span tagx="fnm">JS</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Passchier</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">van Romunde</span>
                  <span tagx="fnm">LK</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Valkenburg</span>
                  <span tagx="fnm">HA</span>
               </li>
            </ul>
            <span tagx="source">J Rheumatol</span>
            <span tagx="pubdate">1991</span>
            <span tagx="volume">18</span>
            <span tagx="fpage">1884</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">1795327</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>WHO reassesses appropriate body-mass index for Asian populations</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Choo</span>
                  <span tagx="fnm">V</span>
               </li>
            </ul>
            <span tagx="source">Lancet</span>
            <span tagx="pubdate">2002</span>
            <span tagx="volume">360</span>
            <span tagx="fpage">235</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/S0140-6736(02)09512-0</span>
                  <span tagx="pubid">12133671</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">FDA/CDER. Guidance for industry estimating the maximum safe starting dose in initial
               clinical trials for therapeutics in adult healthy volunteers; July, 2005, 
               <a href="http://www.fda.gov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm078932.pdf">http://www.fda.gov/downloads/drugs/guidance-complianceregulatoryinformation/guidances/ucm078932.pdf</a>.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">EMEA. Strategies to identify and mitigate risks for first-in-human clinical trialswith
               investigational medicinal products; Sept. 2009, 
               <a href="http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf">http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500002988.pdf</a>.
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="note">Zhang ZL, Li Q, Li QF, Du SM, Zhou YQ, Lv CM, et al. Simultaneous determination of
               nineteen major components in Qishe Pill by ultra-high-performance liquid chromatography–tandem
               mass spectrometry. Acta Pharmaceutica Sinica B (2014); 
               <a href="http://www.dx.doi.org/10.1016/j.apsb.2014.05.003">http://www.dx.doi.org/10.1016/j.apsb.2014.05.003</a>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Evaluation of methods for estimating population pharmacokinetics parameters. I. Michaelis-Menten
                  model: routine clinical pharmacokinetic data
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Sheiner</span>
                  <span tagx="fnm">LB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Beal</span>
                  <span tagx="fnm">SL</span>
               </li>
            </ul>
            <span tagx="source">J Pharmacokinet Biopharm</span>
            <span tagx="pubdate">1980</span>
            <span tagx="volume">8</span>
            <span tagx="fpage">553</span>
            <span tagx="lpage">71</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1007/BF01060053</span>
                  <span tagx="pubid">7229908</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Evaluation of methods for estimating population pharmacokinetic parameters. II. Biexponential
                  model and experi- mental pharmacokinetic data
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Sheiner</span>
                  <span tagx="fnm">BL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Beal</span>
                  <span tagx="fnm">SL</span>
               </li>
            </ul>
            <span tagx="source">J Pharmacokinet Biopharm</span>
            <span tagx="pubdate">1981</span>
            <span tagx="volume">9</span>
            <span tagx="fpage">635</span>
            <span tagx="lpage">51</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1007/BF01061030</span>
                  <span tagx="pubid">7334463</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Evaluation of methods for estimating population pharmacokinetic parameters. III. Monoexponential
                  model: routine clinical pharmacokinetic data
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Sheiner</span>
                  <span tagx="fnm">LB</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Beal</span>
                  <span tagx="fnm">SL</span>
               </li>
            </ul>
            <span tagx="source">J Pharmacokinet Biopharm</span>
            <span tagx="pubdate">1983</span>
            <span tagx="volume">11</span>
            <span tagx="fpage">303</span>
            <span tagx="lpage">19</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1007/BF01061870</span>
                  <span tagx="pubid">6644555</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Population pharmacokinetic analysis for risperidone using highly sparse sampling measurements
                  from the CATIE study
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Feng</span>
                  <span tagx="fnm">Y</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pollock</span>
                  <span tagx="fnm">BG</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Coley</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Marder</span>
                  <span tagx="fnm">S</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Miller</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kirshner</span>
                  <span tagx="fnm">M</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Br J Clin Pharmacol</span>
            <span tagx="pubdate">2008</span>
            <span tagx="volume">66</span>
            <span tagx="fpage">629</span>
            <span tagx="lpage">39</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">18771484</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>An 80-cases clinical observation of two conservative therapy of traditional Chinese
                  and western medicine to cervical spondylotic radiculopathy
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Qingmao</span>
                  <span tagx="fnm">Y</span>
               </li>
            </ul>
            <span tagx="source">Chinese Foreign Health Abs</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">18</span>
            <span tagx="fpage">223</span>
            <span tagx="lpage">5</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Bayesian cost-effectiveness analysis for censored data-an application to antiplatelet
                  therapy
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Bin-Chia Wu</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tsai</span>
                  <span tagx="fnm">YW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wen</span>
                  <span tagx="fnm">YW</span>
               </li>
            </ul>
            <span tagx="source">J Med Econ</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">15</span>
            <span tagx="fpage">434</span>
            <span tagx="lpage">43</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.3111/13696998.2011.653510</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Methylcobalamin increases Erk1/2 and Akt activities through the methylation cycle
                  and promotes nerve regeneration in a rat sciatic nerve injury model
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Okada</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Tanaka</span>
                  <span tagx="fnm">H</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Temporin</span>
                  <span tagx="fnm">K</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Okamoto</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Kuroda</span>
                  <span tagx="fnm">Y</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Moritomo</span>
                  <span tagx="fnm">H</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">Exp Neurol</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">222</span>
            <span tagx="fpage">191</span>
            <span tagx="lpage">203</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.expneurol.2009.12.017</span>
                  <span tagx="pubid">20045411</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Anti-inflammatory activity of astragaloside IV is mediated by inhibition of NF-qB
                  activation and adhesion molecule expression
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">WJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Hufnagl</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Binder</span>
                  <span tagx="fnm">BR</span>
               </li>
            </ul>
            <span tagx="source">Thromb Haemost</span>
            <span tagx="pubdate">2003</span>
            <span tagx="volume">90</span>
            <span tagx="fpage">904</span>
            <span tagx="lpage">14</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">14597987</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Security and pharmacilogical effects of Szechuan Lovage Rhizome extract</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Chen</span>
                  <span tagx="fnm">SL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jiang</span>
                  <span tagx="fnm">GH</span>
               </li>
            </ul>
            <span tagx="source">J Chengdu UnivTradit Chin Med</span>
            <span tagx="pubdate">2009</span>
            <span tagx="volume">32</span>
            <span tagx="fpage">63</span>
            <span tagx="lpage">5</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Clinical research progress of the pharmacology of ovientvine</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Sun</span>
                  <span tagx="fnm">X</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yu</span>
                  <span tagx="fnm">XJ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Qiu</span>
                  <span tagx="fnm">MF</span>
               </li>
            </ul>
            <span tagx="source">J China’s Integrated Tradit Chin Western Med Surg</span>
            <span tagx="pubdate">2005</span>
            <span tagx="volume">11</span>
            <span tagx="fpage">363</span>
            <span tagx="lpage">4</span>
            <div tagx="note"> [In Chinese]</div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Anti-inflammatory effects of Calculus BovisArtifactus: apilot study</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">X</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yu</span>
                  <span tagx="fnm">QH</span>
               </li>
            </ul>
            <span tagx="source">J Shengyang Pharm Univ</span>
            <span tagx="pubdate">2000</span>
            <span tagx="volume">17</span>
            <span tagx="fpage">431</span>
            <span tagx="lpage">3</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Muscone protects vertebral end-plate degeneration by anti-inflammatory property</p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Liang</span>
                  <span tagx="fnm">QQ</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">M</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhou</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Shi</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">YJ</span>
               </li>
            </ul>
            <span tagx="source">ClinOrthop Relat Res</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">468</span>
            <span tagx="fpage">1600</span>
            <span tagx="lpage">10</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1007/s11999-009-1079-0</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Simultaneous determination with HPLC internal standard method for nine kinds ingredients
                  in Qishe Pill
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Du</span>
                  <span tagx="fnm">SM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Pan</span>
                  <span tagx="fnm">YF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">N</span>
               </li>
            </ul>
            <span tagx="source">Chin Tradit Pat Med</span>
            <span tagx="pubdate">2012</span>
            <span tagx="volume">7</span>
            <span tagx="fpage">1271</span>
            <span tagx="lpage">5</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Effects of Qishe Pill on cervical radiculopathy rat model with 
                  <i>Qi-</i>deficiency and 
                  <i>Blood</i>-stasis syndrome
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Du</span>
                  <span tagx="fnm">SM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">QF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">ZL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">N</span>
               </li>
            </ul>
            <span tagx="source">Pharmacol Clin</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">4</span>
            <span tagx="fpage">118</span>
            <span tagx="lpage">21</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>
                  <i>Invivo</i> tissue distribution research of ingredients in Qishe Pill
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Du</span>
                  <span tagx="fnm">SM</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">Q</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">QF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">ZL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">N</span>
               </li>
            </ul>
            <span tagx="source">Chin J Exp Formulas Chin Med</span>
            <span tagx="pubdate">2013</span>
            <span tagx="volume">19</span>
            <span tagx="fpage">171</span>
            <span tagx="lpage">6</span>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Simultaneous analysis of seven astragalosides in Radix Astragali and related preparations
                  by liquid chromatography coupled with electrospray ionization time-of-flight mass
                  spectrometry
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">D</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Song</span>
                  <span tagx="fnm">Y</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">SL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bian</span>
                  <span tagx="fnm">YY</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Guan</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">P</span>
               </li>
            </ul>
            <span tagx="source">J Sep Sci</span>
            <span tagx="pubdate">2006</span>
            <span tagx="volume">29</span>
            <span tagx="fpage">2012</span>
            <span tagx="lpage">22</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/jssc.200500486</span>
                  <span tagx="pubid">17017014</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Determination of seventeen main flavonoids and saponins in the medicinal plant Huang-qi
                  (Radix Astragali) by HPLC-DAD-ELSD
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Yu</span>
                  <span tagx="fnm">QT</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Qi</span>
                  <span tagx="fnm">LW</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yi</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhao</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Bi</span>
                  <span tagx="fnm">ZM</span>
               </li>
            </ul>
            <span tagx="source">J Sep Sci</span>
            <span tagx="pubdate">2007</span>
            <span tagx="volume">30</span>
            <span tagx="fpage">1292</span>
            <span tagx="lpage">9</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1002/jssc.200600422</span>
                  <span tagx="pubid">17623470</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Pharmacokinetics of traditional Chinese syndrome and recipe: a hypothesis and its
                  verification (I)
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Huang</span>
                  <span tagx="fnm">X</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Ren</span>
                  <span tagx="fnm">P</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wen</span>
                  <span tagx="fnm">AD</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Wang</span>
                  <span tagx="fnm">LL</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Zhang</span>
                  <span tagx="fnm">L</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Gao</span>
                  <span tagx="fnm">F</span>
               </li>
            </ul>
            <span tagx="source">World J Gastroenterol</span>
            <span tagx="pubdate">2000</span>
            <span tagx="volume">6</span>
            <span tagx="fpage">384</span>
            <span tagx="lpage">91</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">11819604</span>
               </div>
            </div>
         </div>
         <div tagx="bibl">
            <div tagx="title">
               <p>Pharmacokinetic comparisons of hydroxysafflower yellow A in normal and blood stasis
                  syn- drome rats
               </p>
            </div>
            <ul tagx="aug">
               <li tagx="au">
                  <span tagx="snm">Tian</span>
                  <span tagx="fnm">Y</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yang</span>
                  <span tagx="fnm">ZF</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Li</span>
                  <span tagx="fnm">Y</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Qiao</span>
                  <span tagx="fnm">Y</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Yang</span>
                  <span tagx="fnm">J</span>
               </li>
               <li tagx="au">
                  <span tagx="snm">Jia</span>
                  <span tagx="fnm">YY</span>
               </li>
               <div tagx="etal"></div>
            </ul>
            <span tagx="source">J Ethnopharmacol</span>
            <span tagx="pubdate">2010</span>
            <span tagx="volume">129</span>
            <span tagx="fpage">1</span>
            <span tagx="lpage">4</span>
            <div tagx="xrefbib">
               <div tagx="pubidlist">
                  <span tagx="pubid">10.1016/j.jep.2010.02.023</span>
                  <span tagx="pubid">20206677</span>
               </div>
            </div>
         </div>
      </div>
   </div>
</html>